{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:01:23Z","timestamp":1782212483655,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1124\/dmd.120.000089","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T06:50:14Z","timestamp":1598338214000},"page":"1121-1128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["(\u2013)-N-3-Benzylphenobarbital Is Superior to Omeprazole and (+)-N-3-Benzylnirvanol as a CYP2C19 Inhibitor in Suspended Human Hepatocytes"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-389X","authenticated-orcid":false,"given":"Marie-Lynn","family":"Cuypers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Chanteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gillent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bonnaillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Delatour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Dell\u2019Aiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Ungell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-0085","authenticated-orcid":false,"given":"Johan","family":"Nicola\u00ef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.000089_bib1","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/dmd.115.069096","article-title":"Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions-an industry perspective","volume":"44","author":"Bohnert","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0041-008X(03)00128-5","article-title":"An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons","volume":"189","author":"Brandon","year":"2003","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.120.000089_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/dmd.106.011569","article-title":"Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance","volume":"35","author":"Brown","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/dmd.32.6.584","article-title":"Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes","volume":"32","author":"Cai","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib5","first-page":"1525","article-title":"Root mean square error (RMSE) or mean absolute error (MAE)?","volume":"7","author":"Chai","year":"2014","journal-title":"Geoscientific Model Development Discussions"},{"key":"10.1124\/dmd.120.000089_bib6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00228-012-1428-x","article-title":"CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects","volume":"69","author":"Chan","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000089_bib7","unstructured":"FDA (2020) Guidance for Industry: In Vitro Drug Interaction Studies - Cytochrome, P450, Enzyme- and Transporter-Mediated Drug Interactions. Retrieved from https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."},{"key":"10.1124\/dmd.120.000089_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/dmd.107.019265","article-title":"CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles","volume":"36","author":"Foti","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00498254.2012.719088","article-title":"Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy","volume":"43","author":"Gerin","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.000089_bib10","unstructured":"GraphPad (2020) Equation: log(inhibitor) vs. respons - Variable slope. Retrieved from https:\/\/www.graphpad.com\/guides\/prism\/7\/curve-fitting\/reg_dr_inhibit_variable.htm."},{"key":"10.1124\/dmd.120.000089_bib11","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1517\/17425255.2015.1065814","article-title":"Development of novel tools for the in vitro investigation of drug-induced liver injury","volume":"11","author":"Jiang","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.120.000089_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/dmd.118.084103","article-title":"Characterization of the in vitro inhibitory potential of the oligonucleotide imetelstat on human cytochrome P450 enzymes with predictions of in vivo drug-drug interactions","volume":"47","author":"Kazmi","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-011-0024-2","article-title":"Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity","volume":"36","author":"Khojasteh","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.120.000089_bib14","first-page":"853","article-title":"Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms","volume":"25","author":"Ko","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib15","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/bph.14203","article-title":"Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s","volume":"175","author":"Lindmark","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.120.000089_bib16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/14756366.2010.518965","article-title":"The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors","volume":"26","author":"Liu","year":"2011","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1124\/dmd.120.000089_bib17","first-page":"319","article-title":"Variables in human liver microsome preparation: impact on the kinetics of l-\u03b1-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation","volume":"29","author":"Nelson","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000089_bib19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/00498254.2016.1208854","article-title":"Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model","volume":"47","author":"Parmentier","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.000089_bib20","series-title":"Antiepileptic Drug Interactions: A Clinical Guide","author":"Patsalos","year":"2013"},{"key":"10.1124\/dmd.120.000089_bib21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1011035007591","article-title":"CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects","volume":"18","author":"Sakai","year":"2001","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.120.000089_bib22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/dmd.113.051722","article-title":"Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions","volume":"41","author":"Shirasaka","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib23","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1002\/jps.23262","article-title":"A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes","volume":"101","author":"Smith","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000089_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/clpt.1992.125","article-title":"Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics","volume":"52","author":"Sohn","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000089_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0009-9236(97)90081-3","article-title":"Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4\u2032-hydroxylation phenotype and genotype","volume":"62","author":"Tanaka","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000089_bib27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.120.000089_bib28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/dmd.31.5.565","article-title":"Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19","volume":"31","author":"Yao","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000089_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.000089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:23:45Z","timestamp":1739957025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624078176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0090955624078176"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.000089","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"(\u2013)-N-3-Benzylphenobarbital Is Superior to Omeprazole and (+)-N-3-Benzylnirvanol as a CYP2C19 Inhibitor in Suspended Human Hepatocytes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.000089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}